President Bush has announced a new Medicare-endorsed prescription drug discount card program designed to immediately help Medicare beneficiaries lower their out-of-pocket drug costs.
President Bush has announced a new Medicare-endorsed prescription drug discount card program designed to immediately help Medicare beneficiaries lower their out-of-pocket drug costs.
HHS Secretary Tommy G. Thompson said the president's plan gives immediate help to people with Medicare by providing discounts on drugs while Congress and the administration work to design and implement Medicare coverage for prescription drugs.
"The new discount card program will give seniors greater power to purchase their prescription drugs at a discount," said Thompson. "It will especially help people with Medicare who currently have no prescription drug coverage by lowering the prices they pay for their medications."
Discount cards are expected to save Medicare beneficiaries some 10% to 25% on prescription drug prices. Medicare serves about 40 million beneficiaries, and over 10 million of them do not have prescription drug coverage in addition to their Medicare coverage. The discount program can be implemented quickly, without new legislation, while Congress and the administration work to add a drug benefit to the Medicare program.
Under the Medicare-Endorsed Rx Discount Program, people with Medicare will have the opportunity to learn about and join existing prescription drug discount card organizations. In turn, with larger memberships, the discount card organizations will be able to secure discounts for beneficiaries, just as large insurance plans do.
Easier access to information about the available discount card programs will give Medicare beneficiaries the opportunity to choose the card that best fits their prescription drug needs. A central feature of the discount card program will be the publication of comparative information, including drug prices available under each individual program.
"This program will give people with Medicare the same tools that others are already using to lower their prescription drug costs," Secretary Thompson said. "It is a constructive step that will give immediate relief to those who need it most, as we work to add a drug benefit to Medicare."
All Medicare beneficiaries will be able to enroll in one of several Medicare-endorsed discount card organizations. A small, one-time enrollment fee will be allowed, but it cannot exceed $25.
The plan has come under fire from pharmacy associations that claim it unfairly benefits large pharmacy benefit managers. The National Community Pharmacists Association and the National Association of Chain Drug Stores filed a complaint against Secretary of Health and Human Services Tommy Thompson and Centers for Medicare and Medicaid Services Administrator Tom Scully regarding the administration's discount card initiative. The suit cites a lack of legislative authority on their part, violations of the Administrative Procedures Act and the Federal Advisory Committee Act, and an unlawful delegation of regulatory power to a private consortium.
"This plan provides false hopes to our seniors when they walk into their neighborhood pharmacy," said Craig Fuller, president and chief executive officer of NACDS. "The possibility exists that there are no real discounts on the drugs that their doctors prescribe, that their pharmacy does not participate in the plan, or that they must take a different type of medication than that which was prescribed by their doctor."
The complaint claims that:
•Â HHS set standards for the plan and anticipates spending several million dollars to implement it without Congressional authorization to do so. The law specifically states that in order for HHS to set standards and expend funds, they must have permission from Congress to do so.
•Â HHS set standards for the plan in an unlawful manner. By failing to follow the Administrative Procedures Act, HHS violated the procedure by which plans must be submitted and reviewed.
•Â The Federal Advisory Committee Act requires prior notice and open meetings when developing a government program. HHS met neither of these criteria during the development of the plan.
•Â By setting up the consortium to create, administer and enforce the standards, HHS delegates all power to a private company, which is unlawful.
Enrollment in the Medicare Rx Discount Card Program could begin as early as November 1. PR
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
January 21st 2025Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
January 20th 2025Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer.